drugset / Trial / NCT00914667

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667

Phase 1 Completed 14 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.

Timeline

Start
2009-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 8 mg
Subject Warfarin Small molecule 25 mg

Indications